Vasculitis associated with tumor necrosis factor-α inhibitors

Mayo Clinic Proceedings

Volumn 87, Issue 8, 2012, Pages 739-745

  Sokumbi, Olayemi ^a   Wetter, David A ^a   Makol, Ashima ^a   Warrington, Kenneth J ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; AZATHIOPRINE; CYCLOPHOSPHAMIDE; ETANERCEPT; INFLIXIMAB; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; RITUXIMAB; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

ADULT; ANAPHYLACTOID PURPURA; ARTICLE; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; CROHN DISEASE; CUTANEOUS SMALL CESSEL VASCULITIS; CUTANEOUS SMALL VESEL VASCULITIS; CUTANEOUS SMALL VESSEL VASCULITIS; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; KIDNEY; MALE; OUTCOME ASSESSMENT; PERIPHERAL NERVOUS SYSTEM; PERIPHERAL NEUROPATHY; PURPURA; RETROSPECTIVE STUDY; RHEUMATOID ARTHRITIS; SKIN DEFECT; TREATMENT DURATION; TREATMENT RESPONSE; ULCERATIVE COLITIS; UNITED STATES; VASCULITIS;

EID: 84866387410     PISSN: 00256196     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mayocp.2012.04.011     Document Type: Article

References (20)

1. Atzeni F, Turiel M, Capsoni F, Doria A, Meroni P, Sarzi-Puttini P. Autoimmunity and anti-TNF-α agents. Ann N Y Acad Sci. 2005;1051:559-569.
2. Keystone EC, Ware CF. Tumor necrosis factor and anti-tumor necrosis factor therapies. J Rheumatol Suppl. 2010;85:27-39.
3. Callen JP. Complications and adverse reactions in the use of newer biologic agents. Semin Cutan Med Surg. 2007;26(1):6-14. (Pubitemid 46349778)
4. Mongey AB, Hess EV. Drug insight: autoimmune effects of medications: what's new? Nat Clin Pract Rheumatol. 2008;4(3):136-144. (Pubitemid 351338628)
5. Moustou AE, Matekovits A, Dessinioti C, Antoniou C, Sfikakis PP, Stratigos AJ. Cutaneous side effects of anti-tumor necrosis factor biologic therapy: a clinical review. J Am Acad Dermatol. 2009;61(3):486-504.
6. Scheinfeld N. A comprehensive review and evaluation of the side effects of the tumor necrosis factor alpha blockers etanercept, infliximab and adalimumab. J Dermatolog Treat. 2004;15(5):280-294. (Pubitemid 39423287)
7. Viguier M, Richette P, Bachelez H, Wendling D, Aubin F. Paradoxical cutaneous manifestations during anti-TNF-alpha therapy [in French]. Ann Dermatol Venereol. 2010;137(1):64-71.
8. Ramos-Casals M, Brito-Zeron P, Munoz S, et al. Autoimmune diseases induced by TNF-targeted therapies: analysis of 233 cases. Medicine (Baltimore). 2007;86(4):242-251. (Pubitemid 47067483)
9. Ramos-Casals M, Brito-Zeron P, Soto MJ, Cuadrado MJ, Khamashta MA. Autoimmune diseases induced by TNF-targeted therapies. Best Pract Res Clin Rheumatol. 2008;22(5):847-861.
10. Saint Marcoux B, De Bandt M; CRI (Club Rhumatismes et Inflammation). Vasculitides induced by TNFα antagonists: a study in 39 patients in France. Joint Bone Spine. 2006;73(6):710-713. (Pubitemid 44918417)
11. Ramos-Casals M, Perez-Alvarez R, Diaz-Lagares C, Cuadrado MJ, Khamashta MA; BIOGEAS Study Group. Autoimmune diseases induced by biological agents: a double-edged sword? Autoimmun Rev. 2010;9(3):188-193.
12. Son YM, Lee JR, Roh JY. Causality assessment of cutaneous adverse drug reactions. Ann Dermatol. 2011;23(4):432-438.
13. De Bandt M, Sibilia J, Le Loet X, et al; Club Rhumatismes et Inflammation. Systemic lupus erythematosus induced by antitumour necrosis factor alpha therapy: a French national survey. Arthritis Res Ther. 2005;7(3):R545-R551.
14. Mohan N, Edwards ET, Cupps TR, et al. Leukocytoclastic vasculitis associated with tumor necrosis factor-alpha blocking agents. J Rheumatol. 2004;31(10):1955-1958. (Pubitemid 39336719)
15. Perez-Alvarez R, Perez-de-Lis M, Diaz-Lagares C, et al. Interstitial lung disease induced or exacerbated by TNF-targeted therapies: analysis of 122 cases. Semin Arthritis Rheum. 2011;41(2):256-w64.
16. Wetter DA, Davis MD. Lupus-like syndrome attributable to anti-tumor necrosis factor alpha therapy in 14 patients during an 8-year period at Mayo Clinic. Mayo Clin Proc. 2009;84(11):979-984.
17. Guignard S, Gossec L, Bandinelli F, Dougados M. Comparison of the clinical characteristics of vasculitis occurring during antitumor necrosis factor treatment or not in rheumatoid arthritis patients: a systematic review of 2707 patients, 18 vasculitis. Clin Exp Rheumatol. 2008;26(3, suppl 49):S23-S29.
18. Aringer M, Smolen JS. The role of tumor necrosis factor-alpha in systemic lupus erythematosus. Arthritis Res Ther. 2008;10(1):202.
19. Klein R, Rosenbach M, Kim EJ, Kim B, Werth VP, Dunham J. Tumor necrosis factor inhibitor-associated dermatomyositis. Arch Dermatol. 2010;146(7):780-784.
20. Fiorentino DF. The yin and yang of TNF-α inhibition. Arch Dermatol. 2007;143(2):233-236.